The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 2, 2013, Pages 252-259

  Yang, J J ^a   Lim, J Y S ^a,b   Huang, J ^a   Bass, J ^a   Wu, J ^a   Wang, C ^a   Fang, J ^a   Stewart, E ^a   Harstead, E H ^a   E s , ^a   Robinson, G W ^a   Evans, W E ^a   Pappo, A ^a   Zuo, J ^a   Relling, M V ^a   Onar Thomas, A ^a   Gajjar, A ^a   Stewart, C F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; CISPLATIN; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL DAMAGE; CHILD; CHILDHOOD CANCER; CRANIOSPINAL IRRADIATION; CYTOTOXICITY; DRUG MEGADOSE; GENETIC VARIABILITY; HAIR CELL; HEARING IMPAIRMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LYMPHOBLASTOID CELL LINE; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OTOTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOLID TUMOR; WILD TYPE;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CISPLATIN; CRANIOSPINAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEARING LOSS; HUMANS; MALE; METHYLTRANSFERASES; MICE; MICE, KNOCKOUT;

EID: 84880753477     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.121     Document Type: Article

References (32)

1. Oeffinger, K.C. et al.; Childhood Cancer Survivor Study. Chronic health conditions in adult survivors of childhood cancer. N. Engl. J. Med. 355, 1572-1582 (2006). (Pubitemid 44547808)
2. Knight, K.R., Kraemer, D.F. & Neuwelt, E.A. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J. Clin. Oncol. 23, 8588-8596 (2005). (Pubitemid 46211500)
3. Dolan, M.E. et al. Heritability and linkage analysis of sensitivity to cisplatininduced cytotoxicity. Cancer Res. 64, 4353-4356 (2004). (Pubitemid 38802443)
4. Oldenburg, J., Kraggerud, S.M., Cvancarova, M., Lothe, R.A. & Fossa, S.D. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25, 708-714 (2007). (Pubitemid 350002927)
5. Ross, C.J. et al.; CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349 (2009).
6. Jones, T.S., Yang, W., Evans, W.E. & Relling, M.V. Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism. Clin. Pharmacol. Ther. 81, 729-734 (2007). (Pubitemid 46625112)
7. Huang, R.S. et al. Identification of genetic variants contributing to cisplatininduced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81, 427-437 (2007). (Pubitemid 47330203)
8. Hartford, C. et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res. 67, 4965-4972 (2007). (Pubitemid 46910205)
9. Du, X. et al. A catechol-O-methyltransferase that is essential for auditory function in mice and humans. Proc. Natl. Acad. Sci. USA 105, 14609-14614 (2008).
10. Rybak, L.P. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr. Opin. Otolaryngol. Head Neck Surg. 15, 364-369 (2007). (Pubitemid 47373985)
11. Ciarimboli, G. et al. Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176, 1169-1180 (2010).
12. More, S.S., Akil, O., Ianculescu, A.G., Geier, E.G., Lustig, L.R. & Giacomini, K.M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci. 30, 9500-9509 (2010).
13. Milek, M., Smid, A., Tamm, R., Kuzelicki, N.K., Metspalu, A. & Mlinaric-Rascan, I. Post-translational stabilization of thiopurine S-methyltransferase by S-adenosyl-L-methionine reveals regulation of TPMT*1 and*3C allozymes. Biochem. Pharmacol. 83, 969-976 (2012).
14. Schell, M.J. et al. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J. Clin. Oncol. 7, 754-760 (1989). (Pubitemid 19145597)
15. Paulino, A.C. et al. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 78, 1445-1450 (2010).
16. Tuan, J.K. et al. Late toxicities after conventional radiation therapy alone for nasopharyngeal carcinoma. Radiother. Oncol. 104, 305-311 (2012).
17. Hua, C., Bass, J.K., Khan, R., Kun, L.E. & Merchant, T.E. Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int. J. Radiat. Oncol. Biol. Phys. 72, 892-899 (2008).
18. Fong, R.S., Beste, D.J. & Murray, K.J. Pediatric sensorineural hearing loss after temporal bone radiation. Am. J. Otol. 16, 793-796 (1995).
19. Brock, P.R. et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J. Clin. Oncol. 30, 2408-2417 (2012).
20. Neuwelt, E.A. & Brock, P. Critical need for international consensus on ototoxicity assessment criteria. J. Clin. Oncol. 28, 1630-1632 (2010).
21. Gajjar, A. et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 7, 813-820 (2006). (Pubitemid 44464063)
22. Fouladi, M. et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J. Clin. Oncol. 26, 3749-3755 (2008).
23. Santana, V.M. et al. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J. Clin. Oncol. 23, 4039-4047 (2005). (Pubitemid 46211308)
24. Furman, W.L. et al. A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest. New Drugs 30, 1660-1670 (2012).
25. Chang, K.W. & Chinosornvatana, N. Practical grading system for evaluating cisplatin ototoxicity in children. J. Clin. Oncol. 28, 1788-1795 (2010).
26. Yates, C.R. et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-614 (1997). (Pubitemid 27172187)
27. Kim, H.J. et al. Cisplatin ototoxicity involves cytokines and STAT6 signaling network. Cell Res. 21, 944-956 (2011).
28. Kermany, M.H. et al. Identification of 17 hearing impaired mouse strains in the TMGC ENU-mutagenesis screen. Hear. Res. 220, 76-86 (2006).
29. Wu, X., Gao, J., Guo, Y. & Zuo, J. Hearing threshold elevation precedes hair-cell loss in prestin knockout mice. Brain Res. Mol. Brain Res. 126, 30-37 (2004). (Pubitemid 38781161)
30. Schütz, M. et al. The human deafness-associated connexin 30 T5M mutation causes mild hearing loss and reduces biochemical coupling among cochlear non-sensory cells in knock-in mice. Hum. Mol. Genet. 19, 4759-4773 (2010).
31. Filipski, K.K., Mathijssen, R.H., Mikkelsen, T.S., Schinkel, A.H. & Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402 (2009).
32. Liu, Z., Owen, T., Zhang, L. & Zuo, J. Dynamic expression pattern of Sonic hedgehog in developing cochlear spiral ganglion neurons. Dev. Dyn. 239, 1674-1683 (2010).